Trial Profile
Phase I-II Study of MEK 162 for Children With Low-Grade Gliomas and Other Ras/Raf/ERK Pathway Activated Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary)
- Indications Cancer; Glioma; Tumours
- Focus Therapeutic Use
- 29 Sep 2023 Planned End Date changed from 1 Feb 2024 to 30 Nov 2023.
- 23 Jan 2023 Planned End Date changed from 1 Feb 2023 to 1 Feb 2024.
- 03 Feb 2021 Planned primary completion date changed from 1 Jan 2021 to 1 Nov 2022.